Sinovac Biotech has received a very large order for 5.2 million doses of its H1N1 vaccine, Panflu.1. This is the third order Sinovac has received from various official China agencies, bringing the total to 11.5 million doses. Regarding a separate program, Sinovac also said it won the bidding process to supply its seasonal flu vaccine, Anflu, to the Shanghai government. More details...
Stock Symbol: (NYSE Amex: SVA)
Sorry... this feature or article is only available to subscribers.